Popular filter options for sarcoidosis trials
Sarcoidosis Clinical Trials With No Placebo
View 22 sarcoidosis medical studies that do not have a placebo group.
Diagnostic Test
Routine Screening for Cardiac Sarcoidosis in Sarcoidosis Patients
This trial is testing a new protocol to screen for cardiac sarcoidosis. The routine clinical care is to gather patient's history of symptoms and under go an ECG. If a patient has an abnormal results in standard screening, they typically have further evaluations as part of their routine medical care. These tests might include an echocardiogram, ambulatory ECG, and advanced cardiac imaging (MRI, PET scan as per local practice). A patient that has normal results on standard screening will be randomly assigned to enhanced screening at each center. Half the patients will be randomized to usual follow-up (annual symptom assessment and ECG) and
Corticosteroid
Prednisone/Prednisolone + Methotrexate for Cardiac Sarcoidosis
This trial is comparing the effectiveness of two different doses of Prednisone (or Prednisolone), one standard and one low, in patients with cardiac sarcoidosis who have not yet been treated. The Investigators hypothesize that the low dose will be just as effective as the standard dose, but with better quality of life and less toxicity.
View More Sarcoidosis Trials
See another 3 many medical studies focused on sarcoidosis.
Frequently Asked Questions
Introduction to sarcoidosis
What are the top hospitals conducting sarcoidosis research?
When it comes to advancing the understanding and treatment of sarcoidosis, several hospitals across the United States are at the forefront of clinical trials. In Cincinnati, Ohio, the University of Cincinnati leads with four ongoing sarcoidosis trials and a total of 18 completed trials dedicated to this complex disease. Their first recorded sarcoidosis trial took place in 2006, showcasing their commitment to unraveling its mysteries. Moving eastward to Richmond, Virginia, we find Virginia Commonwealth University making strides in sarcoidosis research as well. With two active trials and three previously conducted studies since their inaugural investigation in 2009, this institution is actively working towards improving outcomes for patients with this enigmatic condition.
Meanwhile, Albany Medical College in Albany has also made significant contributions by conducting two active clinical trials focused on sarcoidosis. Although they have only recently begun their journey into researching this disease (with their first trial taking place in 2015), they are already making an impact on patient care through scientific exploration. Not far from Albany lies Yale University in New Haven, Connecticut—a renowned institution known for its cutting-edge medical research programs. While currently running one active sarcoidosis trial and having completed two earlier investigations since recording their first study in 2013; Yale's contribution highlights its dedication to expanding our knowledge about diagnosing and treating this challenging condition.
Lastly but not leastly adding itself onto these esteemed institutions is Kinevant Study Site situated Minneapolis where researchers focus on developing novel interventions for various diseases including now Sarcodiosis under an ongoing experimentalf sarcoidosis, several hospitals across the United States are at the forefront of clinical trials. In Cincinnati, Ohio, the University of Cincinnati leads with four ongoing sarcoidosis trials and a total of 18 completed trials dedicated to this complex disease. Their first recorded sarcoidosis trial took place in 2006, showcasing their commitment to unraveling its mysteries. Moving eastward to Richmond, Virginia, we find Virginia Commonwealth University making strides in sarcoidosis research as well. With two active trials and three previously conducted studies since their inaugural investigation in 2009, this institution is actively working towards improving outcomes for patients with this enigmatic condition.
Meanwhile, Albany Medical College in Albany has also made significant contributions by conducting two active clinical trials focused on sarcoidosis. Although they have only recently begun their journey into researching this disease (with their first trial taking place in 2015), they are already making an impact on patient care through scientific exploration. Not far from Albany lies Yale University in New Haven, Connecticut—a renowned institution known for its cutting-edge medical research programs. While currently running one active sarcoidosis trial and having completed two earlier investigations since recording their first study in 2013; Yale's contribution highlights its dedication to expanding our knowledge about diagnosing and treating this challenging condition.
Lastly but not leastly adding itself onto these esteemed institutions is Kinevant Study Site situated Minneapolis where researchers focus on developing novel interventions for various diseases including now Sarcodiosis under an ongoing experimental study which marks initiation point back just last year i.e.,in2022.Whilst relatively new entrant among these highly recognized establishments,the Kinevant Study Site showcases promising potential for breakthroughs through innovative approaches.
These hospitals embody hope for those living with sarcoidosis—offering not only access to state-of-the-art treatments but also opportunities to participate in groundbreaking clinical trials that could revolutionize the management of this perplexing disease. Through tireless research and collaboration, these medical centers are making great strides towards improving the lives of sarcoidosis patients across the country and beyond.
Which are the best cities for sarcoidosis clinical trials?
When it comes to sarcoidosis clinical trials, a few cities emerge as key players in advancing research and treatment. Cincinnati, Ohio leads the pack with 7 active trials focusing on interventions like Namilumab, Enhanced Screening Protocol for Cardiac Sarcoidosis, and Efzofitimod 3 mg/kg. Denver, Colorado follows closely behind with 4 ongoing studies exploring similar treatments. Chicago, Illinois and Albany, New York also show promise with 4 active trials each centered around various interventions. Lastly, Boston, Massachusettso sarcoidosis clinical trials, a few cities emerge as key players in advancing research and treatment. Cincinnati, Ohio leads the pack with 7 active trials focusing on interventions like Namilumab, Enhanced Screening Protocol for Cardiac Sarcoidosis, and Efzofitimod 3 mg/kg. Denver, Colorado follows closely behind with 4 ongoing studies exploring similar treatments. Chicago, Illinois and Albany, New York also show promise with 4 active trials each centered around various interventions. Lastly, Boston, Massachusetts contributes to the advancement of knowledge with its own set of 4 trials investigating different approaches such as [64]Cu Macrin and Methotrexate. These cities offer individuals affected by sarcoidosis access to cutting-edge clinical trials that pave the way for improved care options and better outcomes.
Which are the top treatments for sarcoidosis being explored in clinical trials?
Sarcoidosis, a complex disease requiring innovative treatment approaches, is currently being explored through clinical trials. Among the top treatments under investigation are namilumab, anakinra, enhanced screening protocol for cardiac sarcoidosis, and cell-free DNA. Namilumab has one active trial and two all-time sarcoidosis trials since its debut in 2022. Anakinra follows closely with one active trial and one all-time sarcoidosis trial listed in 2020. Additionally, the enhanced screening protocol for cardiac sarcoidosis and cell-free DNA each have one active trial and one all-time sarcoidosis trial after their introduction in 2019. These cutting-edge therapies hold promise for advancing our understanding of this challenging condition and potentially improving patient outcomes moving forward.
What are the most recent clinical trials for sarcoidosis?
Recent clinical trials for sarcoidosis offer hope for improved treatment options. One such trial investigates the effectiveness of XTMAB-16 in comparison to a placebo, providing valuable insights into potential interventions for this condition. Additionally, abrocitinib at a dosage of 200 mg daily is being studied in a phase 2 trial, with the aim of further understanding its efficacy against sarcoidosis symptoms. Acthar gel is also undergoing phase 4 testing to assess its impact on managing sarcoidosis. Another promising avenue being explored is efzofitimod at a dosage of 3 mg/kg in a phase 3 trial, as well as namilumab in ongoing phase 2 research. These trials represent significant advancements towards finding better treatments and enhancing quality of life for those affected by sarcoidosis.
What sarcoidosis clinical trials were recently completed?
Exciting advancements have emerged from recent clinical trials investigating potential treatments for sarcoidosis. In February 2021, Actelion concluded a trial evaluating the efficacy of Selexipag in managing this challenging condition. Stanford University also made significant progress with their Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 study, which wrapped up in September 2019. Additionally, Oregon Health and Science University completed a trial assessing the effectiveness of Corticosteroid treatment in May 2019. While further back in time, Mallinckrodt's Acthar Gel study reached completion in February 2018. These endeavors highlight the ongoing pursuit to identify better therapeutic options for individuals facing sarcoidosis and offer hope for improved management strategies moving forward.